{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:54:35Z","timestamp":1770522875342,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200221"],"award-info":[{"award-number":["82200221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470197"],"award-info":[{"award-number":["82470197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15185-7","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:42:39Z","timestamp":1766137359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolving treatments and outcomes in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a real-world study in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Li","family":"Xiaozhe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Meilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Junru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu","family":"Jingli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Beihui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang","family":"Lifen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"15185_CR1","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9:3.","journal-title":"Med Sci (Basel)"},{"key":"15185_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682\u20139.","journal-title":"Semin Oncol"},{"key":"15185_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2021","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the united States. Leukemia. 2021;36:801\u20138.","journal-title":"Leukemia"},{"key":"15185_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/OP.21.00210","volume":"17","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Vij R. Evolving paradigms of therapy for multiple myeloma: state of the Art and future directions. JCO Oncol Pract. 2021;17:415\u20138.","journal-title":"JCO Oncol Pract"},{"key":"15185_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1182\/blood.2024024140","volume":"143","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Mikhael JR. How can we stamp out high-risk myeloma? Blood. 2024;143:2015\u20136.","journal-title":"Blood"},{"key":"15185_CR6","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/jha2.562","volume":"3","author":"VH Jimenez-Zepeda","year":"2022","unstructured":"Jimenez-Zepeda VH, Reece D, Rigo R, Gogna P, Kong S, Hu XY, et al. Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in canada: a population-based cohort study. EJHaem. 2022;3:1262\u20139.","journal-title":"EJHaem"},{"key":"15185_CR7","doi-asserted-by":"publisher","first-page":"E195","DOI":"10.1002\/ajh.26530","volume":"97","author":"M Mohan","year":"2022","unstructured":"Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, et al. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022;97:E195\u20138.","journal-title":"Am J Hematol"},{"key":"15185_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41408-023-00905-8","volume":"13","author":"J C\u00f4t\u00e9","year":"2023","unstructured":"C\u00f4t\u00e9 J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian myeloma research group database. Blood Cancer J. 2023;13:137.","journal-title":"Blood Cancer J"},{"key":"15185_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936\u201345.","journal-title":"Blood"},{"key":"15185_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29\u201338.","journal-title":"Lancet"},{"key":"15185_CR11","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"15185_CR12","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","volume":"24","author":"J Gu","year":"2018","unstructured":"Gu J, Liu J, Chen M, Huang B, Li J. Longitudinal flow cytometry identified minimal residual disease (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma. Biol Blood Marrow Transpl. 2018;24:2568\u201374.","journal-title":"Biol Blood Marrow Transpl"},{"key":"15185_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"15185_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00277-020-03915-9","volume":"99","author":"L Xu","year":"2020","unstructured":"Xu L, Liu J, Chen M, Kuang L, Huang B, Gu J, et al. Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma. Ann Hematol. 2020;99:581\u20139.","journal-title":"Ann Hematol"},{"key":"15185_CR15","first-page":"e772","volume":"30","author":"O Pasvolsky","year":"2024","unstructured":"Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, et al. Trends in outcomes after upfront autologous transplant for multiple myeloma over three decades. Transpl Cell Ther. 2024;30:e772\u201311.","journal-title":"Transpl Cell Ther"},{"key":"15185_CR16","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1038\/s41409-021-01308-8","volume":"56","author":"K Bergin","year":"2021","unstructured":"Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, et al. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and new Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transpl. 2021;56:2533\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"15185_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","volume":"19","author":"LJ Costa","year":"2013","unstructured":"Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transpl. 2013;19:1615\u201324.","journal-title":"Biol Blood Marrow Transpl"},{"key":"15185_CR18","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00277-021-04481-4","volume":"100","author":"I Toppila","year":"2021","unstructured":"Toppila I, Miettinen T, Lassenius MI, Lievonen J, Bauer M, Anttila P. Characteristics and survival trends in Finnish multiple myeloma patients-a nationwide real-world evidence study. Ann Hematol. 2021;100:1779\u201387.","journal-title":"Ann Hematol"},{"key":"15185_CR19","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.1002\/cam4.5737","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Wang W, Wang Y, Maihemaiti A, Ren L, et al. The evolving diagnosis and treatment paradigms of multiple myeloma in china: 15 years\u2019 experience of 1256 patients in a National medical center. Cancer Med. 2023;12:9604\u201314.","journal-title":"Cancer Med"},{"key":"15185_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1111\/bjh.20062","volume":"206","author":"O Pasvolsky","year":"2025","unstructured":"Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour S, et al. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. Br J Haematol. 2025;206:1730\u20136.","journal-title":"Br J Haematol"},{"key":"15185_CR21","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1007\/s00432-022-04184-x","volume":"149","author":"SY Wang","year":"2022","unstructured":"Wang SY, Holzhey T, Heyn S, Zehrfeld T, Fricke S, Hoffmann FA, et al. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study. J Cancer Res Clin Oncol. 2022;149:3739\u201352.","journal-title":"J Cancer Res Clin Oncol"},{"key":"15185_CR22","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/cam4.3762","volume":"10","author":"L Xu","year":"2021","unstructured":"Xu L, Liu J, Huang B, Kuang L, Gu J, Chen M, et al. Comparison of efficacy, safety, patients\u2019 quality of life, and doctors\u2019 occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma. Cancer Med. 2021;10:1656\u201367.","journal-title":"Cancer Med"},{"key":"15185_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","volume":"36","author":"LB Leypoldt","year":"2022","unstructured":"Leypoldt LB, Besemer B, Asemissen AM, H\u00e4nel M, Blau IW, G\u00f6rner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36:885\u20138.","journal-title":"Leukemia"},{"key":"15185_CR24","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol. 2023;41:3945\u201355.","journal-title":"J Clin Oncol"},{"key":"15185_CR25","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or Lenalidomide and dexamethasone plus autologous transplantation or Carfilzomib plus Lenalidomide and dexamethasone, followed by maintenance with Carfilzomib plus Lenalidomide or Lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"15185_CR26","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"15185_CR27","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.2022018339","volume":"141","author":"A Panopoulou","year":"2023","unstructured":"Panopoulou A, Cairns DA, Holroyd A, Nichols I, Cray N, Pawlyn C, et al. Optimizing the value of Lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the myeloma XI trial. Blood. 2023;141:1666\u201374.","journal-title":"Blood"},{"key":"15185_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao Y, Jin S, Yang D, Pan M, Ouyang W, Liu Y, et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 2024;24:406.","journal-title":"BMC Cancer"},{"key":"15185_CR29","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/j.clml.2021.12.009","volume":"22","author":"V Abello","year":"2022","unstructured":"Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-world evidence of epidemiology and clinical outcomes in multiple myeloma, findings from the registry of hemato-oncologic malignancies in Colombia, observational study. Clin Lymphoma Myeloma Leuk. 2022;22:e405\u201313.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"15185_CR30","doi-asserted-by":"publisher","first-page":"113921","DOI":"10.1016\/j.ejca.2024.113921","volume":"201","author":"N Abildgaard","year":"2024","unstructured":"Abildgaard N, Anttila P, Waage A, Rubin KH, \u00d8rstavik S, Bent-Ennakhil N, et al. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and sweden: an analysis using linked nordic registries. Eur J Cancer. 2024;201:113921.","journal-title":"Eur J Cancer"},{"key":"15185_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/jcm10010105","volume":"10","author":"K Akizuki","year":"2020","unstructured":"Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, et al. Real-world data on clinical features, outcomes, and prognostic factors in multiple myeloma from Miyazaki prefecture, Japan. J Clin Med. 2020;10:105.","journal-title":"J Clin Med"},{"key":"15185_CR32","doi-asserted-by":"publisher","first-page":"844779","DOI":"10.3389\/fonc.2022.844779","volume":"12","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Bertuglia G, Oliva S. Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results. Front Oncol. 2022;12:844779.","journal-title":"Front Oncol"},{"key":"15185_CR33","doi-asserted-by":"publisher","first-page":"e0208507","DOI":"10.1371\/journal.pone.0208507","volume":"13","author":"K Remes","year":"2018","unstructured":"Remes K, Anttila P, Silvennoinen R, Putkonen M, Ollikainen H, Ter\u00e4v\u00e4 V, et al. Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009\u20132013. PLoS ONE. 2018;13:e0208507.","journal-title":"PLoS ONE"},{"key":"15185_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3324\/haematol.2017.178103","volume":"103","author":"CH Blimark","year":"2018","unstructured":"Blimark CH, Turesson I, Genell A, Ahlberg L, Bj\u00f6rkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103:506\u201313.","journal-title":"Haematologica"},{"key":"15185_CR35","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","volume":"22","author":"EC Scott","year":"2016","unstructured":"Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, et al. Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis. Biol Blood Marrow Transpl. 2016;22:1893\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"15185_CR36","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"15185_CR37","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","volume":"35","author":"J Corre","year":"2021","unstructured":"Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, et al. Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods. Leukemia. 2021;35:3600\u20133.","journal-title":"Leukemia"},{"key":"15185_CR38","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous Haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and Lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456\u201368.","journal-title":"Lancet Haematol"}],"updated-by":[{"DOI":"10.1186\/s12885-026-15681-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15185-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15185-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15185-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:28:10Z","timestamp":1770445690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15185-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15185"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15185-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Figure 4 has been revised.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-026-15681-4","URL":"https:\/\/doi.org\/10.1186\/s12885-026-15681-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University. Informed consent was obtained from all participants or their legal guardians before inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent to the publication of this manuscript in its current form. Consent for publication was obtained from all patients or legal guardians included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1875"}}